scholarly journals Multimodality Imaging in Transcatheter Aortic Valve Implantation and Post-Procedural Aortic Regurgitation

2011 ◽  
Vol 58 (21) ◽  
pp. 2165-2173 ◽  
Author(s):  
Andrew Jabbour ◽  
Tevfik F. Ismail ◽  
Neil Moat ◽  
Ankur Gulati ◽  
Isabelle Roussin ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Regurgitation ◽  
Transcatheter Aortic Valve Implantation ◽  
Multimodality Imaging ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Multimodality imaging throughout transcatheter aortic valve implantation

2012 ◽  
Vol 8 (3) ◽  
pp. 413-424 ◽  
Author(s):  
Linda M de Heer ◽  
Jolanda Kluin ◽  
Pieter R Stella ◽  
Gertjan TJ Sieswerda ◽  
Willem P Th M Mali ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Multimodality Imaging ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Transcatheter aortic valve implantation

2021 ◽  
pp. 315-336
Author(s):  
Arnold C.T. Ng ◽  
Victoria Delgado ◽  
Jeroen J. Bax
Keyword(s):  
Computed Tomography ◽  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Transthoracic Echocardiography ◽  
Multimodality Imaging ◽  
Imaging Modality ◽  
Severe Aortic Stenosis ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Transcatheter aortic valve implantation (TAVI) is an established therapy for patients with symptomatic severe aortic stenosis and contraindications for surgical aortic valve replacement or with intermediate and high operative risk in whom the heart team considers that TAVI is the best therapeutic option. Accurate patient selection strongly relates on multimodality imaging consisting mostly of the combination of transthoracic echocardiography and computed tomography. To guide the procedure, fluoroscopy is the mainstay imaging modality. In the follow-up of the patients, transthoracic echocardiography and computed tomography are again the main imaging modalities to use. Cardiovascular magnetic resonance and nuclear imaging have a minimal role in this area.

P1676De novo aortic insufficiency following long term LVAD support can be successfully treated with TAVI and a pre-stenting technique

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
M Kofler ◽  
A Unbehaun ◽  
S Buz ◽  
C Klein ◽  
A Meyer ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Regurgitation ◽  
Transcatheter Aortic Valve Implantation ◽  
High Rate ◽  
Landing Zone ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation ◽  
Lvad Support

Abstract Background/Introduction Long-term continuous flow left ventricular assist device (cf-LVAD) can result in the development of relevant aortic regurgitation (AR). Although its impact on survival is still controversial, it causes heart failure related symptoms. Current evidence for less invasive strategies to treat AR in cf-LVAD patients is limited. Purpose This study sought to investigate the value of transcatheter aortic valve implantation (TAVI) to treat severe de novo AR in patients on long-term cf-LVAD support. Methods We performed a retrospective analysis of 13 patients with severe AR following cf-LVAD implantation treated with TAVI between 2010 and 2019. TAVI's were performed via transfemoral (n=11), transapical (n=1) and transaxillary (n=1) access route. CoreValve (n=2), LotusValve (n=1), SapienXT (n=1) and Sapien3 (n=9) were used as transcatheter heart valves. In 4 patients, a new off-label strategy using landing-zone pre-stenting with a Sinus-XL stent was used (Figure 1). Results The median time interval from LVAD-implantation to TAVI was 1.7 years [interquartile range (IQR): 1.0 - 3.1]. Median age was 62 years [IQR: 57 - 67]. No procedural mortality or stroke was observed. Overall, device success according to VARC-II criteria was low due to a high rate of second valve necessity (54%). In contrast to the standard implantation technique, device success was 100% when the newly developed pre-stenting technique was applied (Table 1). Aortic regurgitation at discharge was none/trace in all patients. Valve function remained stable in all patients during a median echocardiographic follow-up time of 105 days [IQR: 11 - 298]. Table 1 Overall Sinus-XL prestenting (n=4) NO prestenting (n=9) Device success 7 (54) 4 (100) 3 (33) Procedural mortality 0 (0) 0 (0) 0 (0) Correct positioning of a single valve 7 (54) 4 (100) 3 (33) Intended valve performance 13 (100) 4 (100) 9 (100) Moderate or severe aortic regurgitation 0 (0) 0 (0) 0 (0) Figure 1 Conclusions Transcatheter aortic valve implantation is an efficient tool to treat cf-LVAD induced severe AR. The challenging anatomy of the non-calcified device landing zone causes a relatively high rate of primary device failure, which could be overcome with a pre-stenting technique. Acknowledgement/Funding None

scholarly journals Aortic Regurgitation After Transcatheter Aortic Valve Implantation With Balloon- and Self-Expandable Prostheses

2014 ◽  
Vol 7 (3) ◽  
pp. 284-292 ◽  
Author(s):  
Mohamed Abdel-Wahab ◽  
Thomas Comberg ◽  
Heinz Joachim Büttner ◽  
Mohamed El-Mawardy ◽  
Kenichi Chatani ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Regurgitation ◽  
Transcatheter Aortic Valve Implantation ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

scholarly journals Aortic Regurgitation Index Defines Severity of Peri-Prosthetic Regurgitation and Predicts Outcome in Patients After Transcatheter Aortic Valve Implantation

2012 ◽  
Vol 59 (13) ◽  
pp. 1134-1141 ◽  
Author(s):  
Jan-Malte Sinning ◽  
Christoph Hammerstingl ◽  
Mariuca Vasa-Nicotera ◽  
Viktoria Adenauer ◽  
Sisa Josefina Lema Cachiguango ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Regurgitation ◽  
Transcatheter Aortic Valve Implantation ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation
Sign in / Sign up

Export Citation Format

Share Document